Literature DB >> 26026420

The code of non-coding RNAs in lung fibrosis.

Huachun Cui1, Na Xie, Victor J Thannickal, Gang Liu.   

Abstract

The pathogenesis of pulmonary fibrosis is a complicated and complex process that involves phenotypic abnormalities of a variety of cell types and dysregulations of multiple signaling pathways. There are numerous genetic, epigenetic and post-transcriptional mechanisms that have been identified to participate in the pathogenesis of this disease. However, efficacious therapeutics developed from these studies have been disappointingly limited. In the past several years, a group of new molecules, i.e., non-coding RNAs (ncRNAs), has been increasingly appreciated to have critical roles in the pathological progression of lung fibrosis. In this review, we summarize the recent findings on the roles of ncRNAs in the pathogenesis of this disorder. We analyze the translational potential of this group of molecules in treating lung fibrosis. We also discuss challenges and future opportunities of studying and utilizing ncRNAs in lung fibrosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26026420      PMCID: PMC4550527          DOI: 10.1007/s00018-015-1939-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  118 in total

Review 1.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 2.  MicroRNA biogenesis: coordinated cropping and dicing.

Authors:  V Narry Kim
Journal:  Nat Rev Mol Cell Biol       Date:  2005-05       Impact factor: 94.444

Review 3.  Molecular mechanisms of long noncoding RNAs.

Authors:  Kevin C Wang; Howard Y Chang
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

4.  Mnt: a novel Max-interacting protein and Myc antagonist.

Authors:  P J Hurlin; C Qúeva; R N Eisenman
Journal:  Curr Top Microbiol Immunol       Date:  1997       Impact factor: 4.291

5.  RNA polymerase III transcribes human microRNAs.

Authors:  Glen M Borchert; William Lanier; Beverly L Davidson
Journal:  Nat Struct Mol Biol       Date:  2006-11-12       Impact factor: 15.369

Review 6.  Origins and Mechanisms of miRNAs and siRNAs.

Authors:  Richard W Carthew; Erik J Sontheimer
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

7.  The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis.

Authors:  Haihai Liang; Chaoqian Xu; Zhenwei Pan; Ying Zhang; Zhidan Xu; Yingzhun Chen; Tianyu Li; Xuelian Li; Ying Liu; Longtao Huangfu; Ying Lu; Zhihua Zhang; Baofeng Yang; Samuel Gitau; Yanjie Lu; Hongli Shan; Zhimin Du
Journal:  Mol Ther       Date:  2014-03-05       Impact factor: 11.454

8.  Fibrotic extracellular matrix activates a profibrotic positive feedback loop.

Authors:  Matthew W Parker; Daniel Rossi; Mark Peterson; Karen Smith; Kristina Sikström; Eric S White; John E Connett; Craig A Henke; Ola Larsson; Peter B Bitterman
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

9.  MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines.

Authors:  S Grosso; J Doyen; S K Parks; T Bertero; A Paye; B Cardinaud; P Gounon; S Lacas-Gervais; A Noël; J Pouysségur; P Barbry; N M Mazure; B Mari
Journal:  Cell Death Dis       Date:  2013-03-14       Impact factor: 8.469

Review 10.  Development of microRNA therapeutics is coming of age.

Authors:  Eva van Rooij; Sakari Kauppinen
Journal:  EMBO Mol Med       Date:  2014-07       Impact factor: 12.137

View more
  6 in total

1.  miR-34a Inhibits Lung Fibrosis by Inducing Lung Fibroblast Senescence.

Authors:  Huachun Cui; Jing Ge; Na Xie; Sami Banerjee; Yong Zhou; Veena B Antony; Victor J Thannickal; Gang Liu
Journal:  Am J Respir Cell Mol Biol       Date:  2017-02       Impact factor: 6.914

Review 2.  ncRNA-regulated immune response and its role in inflammatory lung diseases.

Authors:  Na Xie; Gang Liu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

Review 3.  Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?

Authors:  Sunad Rangarajan; Morgan L Locy; Tracy R Luckhardt; Victor J Thannickal
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

4.  MicroRNA-27a-3p Is a Negative Regulator of Lung Fibrosis by Targeting Myofibroblast Differentiation.

Authors:  Huachun Cui; Sami Banerjee; Na Xie; Jing Ge; Rui-Ming Liu; Sadis Matalon; Victor J Thannickal; Gang Liu
Journal:  Am J Respir Cell Mol Biol       Date:  2016-06       Impact factor: 6.914

Review 5.  Recent advances in understanding idiopathic pulmonary fibrosis.

Authors:  Cécile Daccord; Toby M Maher
Journal:  F1000Res       Date:  2016-05-31

Review 6.  Potential contribution of alveolar epithelial type I cells to pulmonary fibrosis.

Authors:  Michael Kasper; Kathrin Barth
Journal:  Biosci Rep       Date:  2017-11-21       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.